Calcium Pidolate

Calcium pidolate is a chelated calcium salt formed by binding calcium to pidolic acid (pyroglutamic acid), a naturally occurring amino acid derivative. The pidolate ligand stabilizes calcium in the alkaline intestinal environment, theoretically improving absorption compared to inorganic salts like calcium carbonate by preventing precipitation as insoluble calcium phosphate.

Origin & History

Calcium pidolate is a synthetic organometallic compound consisting of calcium chelated to two molecules of pidolate (pyrrolidone carboxylic acid), derived from the cyclized form of L-glutamic acid. It is produced industrially by first cyclizing L-glutamic acid to form L-pidolic acid, then reacting it with calcium carbonate or calcium hydroxide in aqueous medium to yield the stable chelate C₁₀H₁₂CaN₂O₆.

Historical & Cultural Context

No historical or traditional medicinal uses for calcium pidolate are documented in the research dossier. As a synthetic compound, it lacks traditional usage history.

Health Benefits

• Enhanced calcium bioavailability through stable chelation that prevents precipitation in intestinal alkaline environment (mechanism described, no clinical trials cited)
• Direct assimilation by bone structures due to pidolate acting as organic carrier (manufacturer claim, no clinical evidence provided)
• Better intestinal mucosa tolerance compared to inorganic calcium salts like chloride or gluconate (claimed advantage, no clinical studies referenced)
• Improved calcium solubility maintenance throughout digestive tract via bidentate ligand binding (biochemical property, no human trials)
• Potential protein support function from pidolate component absent in other calcium forms (theoretical benefit, no clinical validation)

How It Works

Calcium pidolate dissociates to release calcium ions and pidolic acid (5-oxoproline) in the gastrointestinal tract; the chelate bond resists alkaline-induced precipitation that limits inorganic calcium salts, keeping calcium soluble for passive paracellular and active transcellular transport via TRPV6 channels in enterocytes. Absorbed calcium then enters systemic circulation and is regulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D3 (calcitriol), which upregulate calbindin-D9k to facilitate intracellular calcium shuttling. The pidolate moiety is independently metabolized via the glutathione synthesis pathway, though its contribution to bone matrix deposition beyond a calcium-carrier role has not been confirmed by peer-reviewed mechanistic studies.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses for calcium pidolate were found in the research dossier. The available information consists solely of chemical descriptions and proposed mechanisms without clinical validation or PubMed references.

Clinical Summary

Direct clinical trial data specifically investigating calcium pidolate are extremely limited in the published literature, making it difficult to draw firm conclusions about its superiority over other calcium forms. Most evidence supporting enhanced bioavailability is extrapolated from general chelated calcium research or derives from in vitro solubility studies and manufacturer-sponsored documentation rather than randomized controlled trials. One area of referenced use involves pediatric and geriatric populations where organic calcium salts are promoted for gentler gastrointestinal tolerability, but no large-scale (n>200) head-to-head RCTs comparing calcium pidolate to calcium carbonate or citrate in bone density outcomes have been identified in major databases as of early 2025. Consumers should interpret bioavailability claims cautiously given the current evidence gap.

Nutritional Profile

Calcium Pidolate is a calcium salt of pidolic acid (pyroglutamic acid), functioning purely as a mineral supplement with no macronutrient contribution. Elemental calcium content: approximately 12-13% by molecular weight (molecular weight of calcium pidolate ~296 g/mol, with one calcium ion per molecule yielding ~40g Ca per 296g compound). Contains no dietary fiber, protein, fat, or vitamins. The pidolate (pyroglutamate) anion is a cyclic derivative of glutamic acid and constitutes the organic carrier component (~87-88% of molecular weight). Bioavailability is considered enhanced relative to inorganic calcium salts (e.g., calcium carbonate ~40% elemental Ca but poor solubility at neutral pH; calcium chloride ~36% elemental Ca but poor GI tolerance) due to the chelated organic structure maintaining solubility in the alkaline intestinal environment, theoretically reducing calcium precipitation as insoluble calcium phosphate or carbonate. The pidolate ligand may facilitate transcellular and paracellular intestinal absorption pathways, though direct comparative absorption data from controlled human trials is limited. No significant micronutrient co-factors are inherently present; absorption remains dependent on adequate vitamin D status and gastric acid secretion as with all calcium forms. Typical supplement dosing provides 500-1000 mg elemental calcium equivalent per day when properly dosed by salt weight.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details for calcium pidolate are available from the research provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Vitamin K2, Magnesium, Boron, Silicon

Safety & Interactions

Calcium pidolate is generally considered safe at standard supplemental doses (500–1000 mg elemental calcium daily), with side effects typical of calcium supplementation including mild constipation, bloating, and nausea, though the organic chelate form may produce fewer gastrointestinal complaints than calcium carbonate. Excessive calcium intake (above 2500 mg elemental calcium daily for adults) risks hypercalcemia, nephrolithiasis, and potential cardiovascular effects as suggested by some observational data. Calcium supplements broadly interact with several drug classes: they reduce absorption of bisphosphonates, fluoroquinolone and tetracycline antibiotics, levothyroxine, and iron supplements when co-administered, requiring 2–4 hour separation. Calcium pidolate should be used cautiously in patients with hypercalcemia, renal insufficiency, or sarcoidosis; pregnancy safety follows general calcium guidelines (adequate intake 1000–1300 mg/day), and supplementation is considered safe during lactation under medical supervision.